The KPNA3 Knockout NCI-H1975 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the KPNA3 gene in a human lung adenocarcinoma background. CRISPR/Cas9-mediated gene disruption targets KPNA3, which encodes importin alpha-3, a key nuclear transport receptor. This polyclonal pool comprises a heterogeneous mix of edited alleles, providing a population-level knockout model without clonal selection, suitable for studying the functional consequences of KPNA3 ablation on nucleocytoplasmic trafficking and downstream signaling.
The host NCI-H1975 cell line is a widely used human lung adenocarcinoma model derived from a non-small cell lung cancer (NSCLC) patient. It carries the activating epidermal growth factor receptor (EGFR) L858R mutation, a common oncogenic driver in NSCLC. This genetic background renders NCI-H1975 cells dependent on EGFR signaling for proliferation and survival, making them a relevant system for investigating EGFR-associated nuclear transport mechanisms and for evaluating targeted therapies.
KPNA3 belongs to the importin alpha family and functions as an adaptor that recognizes classical nuclear localization signals (cNLS) on cargo proteins, forming a trimeric complex with importin beta (KPNB1) and Ran GTPase to facilitate nuclear import. KPNA3 mediates the translocation of transcription factors such as NF-??B p65, STAT3, p53, and c-MYC, thereby directly influencing their transcriptional activities. The gene is regulated by upstream signals including EGFR, MYC, and NF-??B itself, and it interacts with nucleoporins and Ran during the import cycle. KPNA3-dependent transport is integral to the NF-??B, MAPK, and p53 signaling cascades.
In the NCI-H1975 EGFR-mutant background, disruption of KPNA3 is expected to impair the nuclear localization of these transcription factors, potentially attenuating oncogenic signaling driven by EGFR and altering cellular responses to growth factors, stress, and therapeutic agents. The knockout model thus provides a unique tool to dissect the role of nucleocytoplasmic transport in EGFR-mediated pathogenesis and to explore how aberrant nuclear import contributes to lung adenocarcinoma progression. The polyclonal nature captures a range of editing events, reflecting the heterogeneous consequences of KPNA3 loss in a tumor cell context.
Researchers can employ the KPNA3 Knockout NCI-H1975 Polyclonal Cells for a variety of experimental applications, including immunofluorescence-based analysis of transcription factor subcellular distribution, co-immunoprecipitation to examine KPNA3 interactomes, and RNA sequencing to profile transcriptomic changes upon nuclear transport disruption. The model is also suitable for cell viability and drug sensitivity assays to screen for nuclear transport inhibitors or to assess synergy with EGFR-targeted therapies. Reporter gene assays can monitor NF-??B or STAT3 activity, providing functional readouts of KPNA3-mediated transport. For additional details or support, please contact Ascent Research.
